Roger Tell

Chief Tech/Sci/R&D Officer presso ISOFOL MEDICAL AB

59 anni

Health Technology

Consumer Services

Profilo

Roger Tell is currently the Director at Vivesto AB since 2022 and the Chief Scientific & Medical Officer at Isofol Medical AB since 2019.
Previously, he worked as the Vice President-Clinical Development at Aprea Therapeutics AB.
Dr. Tell obtained his doctorate degree from Karolinska Institutet in 1998.

Posizioni attive di Roger Tell

Società	Posizione	Inizio
ISOFOL MEDICAL AB	Chief Tech/Sci/R&D Officer	01/02/2019
VIVESTO AB	Director/Board Member	25/05/2022

Tutte le posizioni attive di Roger Tell

Precedenti posizioni note di Roger Tell

Società	Posizione	Fine
Aprea Therapeutics AB Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.	Corporate Officer/Principal	01/02/2019

Vedi nel dettaglio l'esperienza di Roger Tell

Formazione di Roger Tell

Karolinska Institutet

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Roger Tell

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
VIVESTO AB	Health Technology
ISOFOL MEDICAL AB	Health Technology

Aziende private	1
Aprea Therapeutics AB Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.	Health Technology